ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of $1.21, $0.23 better than the analyst estimate of $0.98. Revenue for the quarter came in at $137.4 million versus the consensus estimate of $125.35 million.

GUIDANCE:

ANI Pharma sees FY2024 EPS of $4.26-$4.67, versus the consensus of $4.48. ANI Pharma sees FY2024 revenue of $520-542 million, versus the consensus of $535.11 million. Adjusted non-GAAP EBITDA of $135 million to $145 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.